Big Pharma Would Like Your DNA
23andMe’s $300 million deal with GlaxoSmithKline is just the tip of the iceberg.
Updated on July 28, 2018
23andMe has always planned to sell access to its customers’ DNA—a fact it has not exactly kept secret.
When the company’s DNA-testing service launched in 2007, its quest to amass a “treasure trove of data ... to drive research forward” as a “key part of the 23andMe business plan.” Co-founders Anne Wojcicki and Linda Avey outright thatselling kits was only the first step. “The long gamein 2013. “Once you have the data, [the company] does actually become the Google of personalized health care.”
